mutations, in whom rituximab seems to get small additional worth.59 Other genomic subgroups, for instance people with BIRC3 gene in clients relapsing immediately after cure Along with the BCL2 antagonist venetoclax. 66 Resistance to these brokers has become connected with these mutations in close